» Summit Reports Positive Interim Data from Phase 1 Testing a New Formulation of SMT C1100 in DMD Patients Action Duchenne: "Today, we announced preliminary interim results from an ongoing Phase 1 trial of a new formulation of SMT C1100. As you’ll see in the release pasted below, we just announced data from the first dose in patients (with up to 3 doses planned) and from healthy volunteers. The data are encouraging and the trial is proceeding to the next dose in patients. This new formulation Phase 1 trial is a separate trial to the Phase 2 PhaseOut DMD trial that we’ve been discussing recently. Some questions that you may have:"
'via Blog this'
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment